Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women’s Health Portfolio
Organon & Co. (NYSE:OGN) is a pharmaceutical company focused on women’s health and biosimilars.
Organon & Co. (OGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 9,090,467 | $87,995,721 | +830% | 0.04% |
| 2. | Citadel Investment Group Ken Griffin | 5,462,410 | $52,876,129 | +37% | 0.01% |
| 3. | Kahn Brothers Irving Kahn | 3,490,150 | $33,784,652 | +40% | 6.78% |
| 4. | AQR Capital Management Cliff Asness | 3,254,884 | $31,507,278 | +137% | 0.03% |
| 5. | Gotham Asset Management Joel Greenblatt | 2,705,513 | $26,189,366 | +94% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.07 | 12,469 | $100,591.16 | 12,469 | 2025-05-14 | Filing | |
| $8.77 | 5,500 | $48,235.00 | 62,974 | 2025-05-07 | Filing | |
| $9.21 | 8,045 | $74,054.23 | 52,489 | 2025-05-06 | Filing | |
| $8.24 | 3,500 | $28,828.10 | 46,669 | 2025-05-06 | Filing | |
| $8.82 | 11,400 | $100,548.00 | 144,484 | 2025-05-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 32,277,543 | $312,446,616 | 0.01% | |
| 2. | 31,142,122 | $301,455,740 | 0.01% | |
| 3. | 10,237,203 | $99,096,126 | 0.03% | |
| 4. | 9,520,594 | $92,159,350 | 0% | |
| 5. | 5,959,792 | $57,690,787 | 0.01% |
News See All
10 Overlooked Healthcare Stocks to Invest in
Most Americans have endured the frustration of having their health insurance denied, often with no resolution even after contacting carriers by phone and email. This can be changed by Dr.
Organon & Co. (OGN) Reports Q2 2025 Results
Organon & Co. (NYSE:OGN) is one of the top oversold NYSE stocks to buy now. Organon & Co.
10 Oversold NYSE Stocks to Buy Now
nasHe made the argument that dips should be bought, reasoning that most institutional investors believe we are likely to experience a growth scare, possibly a stagflation scare, from August through October...
Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings
In its updated report, Organon & Co. (NYSE:OGN) said net income declined by 26 percent to $145 million from $195 million in the same period last year, while revenues dipped by 1 percent to $1.59 billion...
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Organon Second Quarter 2025 Earnings Call and Webcast.
10 Most Undervalued Pharma Stocks to Buy Now
Pharmaceutical manufacturing in the U.S. has declined sharply over recent decades, with most active ingredient production shifting overseas due to lower labor costs. In 2023, the U.S.
13 Best Healthcare Stocks to Buy Under $10
On June 27, Tiffany McGhee, CEO of Pivotal Advisors, appeared on CNBC to talk about the best course of action for investors amid current market dynamics.
Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program
Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co.
Hedge Fund Resource Center Billionaire Hedge Funds
